摘要
Aryl hydrocarbon receptor(AHR)was considered to be an important pan-tumor therapeutic target,but small molecule inhibitors targeting AHR target gene ID01 have failed in clinical trials.The recent paper published in Cell by Opitz et al.explained the failure of previous clinical trials and identified new therapeutic targets(Fig.1).
基金
This work was supported by the National Natural Science Foundation of China[81672787,82072594,Y.T.,81972638,W.L.,82002916,C.M.]
China Postdoctoral Science Foundation[2019M652804,CM.]
Natural Science Foundation of Hunan Province[2020JJ5790,C.M.]
Hunan Provincial Key Area R&D Programs[2019SK2253,Y.T.]
Postdoctoral Foundation of Central South University[220372,C.M.]
Shenzhen Science and Technology Program[KQTD20170810160226082]
Shenzhen Municipal Government of China[JCYJ20180507184647104].
